A5073980332- Bone and Joint Diseases
- Bone health and treatments
- Colorectal Cancer Treatments and Studies
- Rheumatoid Arthritis Research and Therapies
- Multiple and Secondary Primary Cancers
- Renal cell carcinoma treatment
- Cancer Treatment and Pharmacology
- Bone health and osteoporosis research
- Genetic factors in colorectal cancer
Adjuvant capecitabine and oxaliplatin (CAPOX) is a standard treatment for resected colon cancer; however, in patients with moderate renal impairment, the incidence of CAPOX-related adverse events (AEs) rate early discontinuation are higher than no or mild impairment. The aim this retrospective study was to assess impact baseline function on safety adjuvant CAPOX therapy started dose elderly cancer.Data from aged ≥65 years old who received at starting as stage II/III cancer were collected...
The favorable safety and consistent effectiveness of monthly intravenous (IV) ibandronate injections was demonstrated in a prospective, postmarketing, observational study Japanese patients with osteoporosis. Here, we present subgroup analyses from the study. Lumbar spine (L2–4) bone mineral density (BMD) gains were assessed following subgroups: aged <75 or ≥75 years, absence presence vertebral fractures, previous bisphosphonate (BP) treatment, concomitant versus naïve osteoporosis drug...
This postmarketing, observational study evaluated the safety and effectiveness of monthly intravenous (IV) ibandronate in Japanese patients with osteoporosis.